CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets. / Martel, Cyril Jean-Marie; Agger, Else Marie; Poulsen, Julie Juul; Jensen, Trine Hammer; Andresen, Lars; Christensen, Dennis; Nielsen, Lars Peter; Blixenkrone-Møller, Merete; Andersen, Peter; Aasted, Bent.

I: P L o S One, Bind 6, Nr. 8, 2011.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Martel, CJ-M, Agger, EM, Poulsen, JJ, Jensen, TH, Andresen, L, Christensen, D, Nielsen, LP, Blixenkrone-Møller, M, Andersen, P & Aasted, B 2011, 'CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets', P L o S One, bind 6, nr. 8. https://doi.org/10.1371/journal.pone.0022891

APA

Martel, C. J-M., Agger, E. M., Poulsen, J. J., Jensen, T. H., Andresen, L., Christensen, D., Nielsen, L. P., Blixenkrone-Møller, M., Andersen, P., & Aasted, B. (2011). CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets. P L o S One, 6(8). https://doi.org/10.1371/journal.pone.0022891

Vancouver

Martel CJ-M, Agger EM, Poulsen JJ, Jensen TH, Andresen L, Christensen D o.a. CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets. P L o S One. 2011;6(8). https://doi.org/10.1371/journal.pone.0022891

Author

Martel, Cyril Jean-Marie ; Agger, Else Marie ; Poulsen, Julie Juul ; Jensen, Trine Hammer ; Andresen, Lars ; Christensen, Dennis ; Nielsen, Lars Peter ; Blixenkrone-Møller, Merete ; Andersen, Peter ; Aasted, Bent. / CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets. I: P L o S One. 2011 ; Bind 6, Nr. 8.

Bibtex

@article{a675e2d9cd0b41e980d0866ac1776753,
title = "CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets",
abstract = "Trivalent inactivated vaccines (TIV) against influenza are given to 350 million people every year. Most of these are non-adjuvanted vaccines whose immunogenicity and protective efficacy are considered suboptimal. Commercially available non-adjuvanted TIV are known to elicit mainly a humoral immune response, whereas the induction of cell-mediated immune responses is negligible. Recently, a cationic liposomal adjuvant (dimethyldioctadecylammonium/trehalose 6,6'-dibehenate, CAF01) was developed. CAF01 has proven to enhance both humoral and cell-mediated immune responses to a number of different experimental vaccine candidates. In this study, we compared the immune responses in ferrets to a commercially available TIV with the responses to the same vaccine mixed with the CAF01 adjuvant. Two recently circulating H1N1 viruses were used as challenge to test the vaccine efficacy. CAF01 improved the immunogenicity of the vaccine, with increased influenza-specific IgA and IgG levels. Additionally, CAF01 promoted cellular-mediated immunity as indicated by interferon-gamma expressing lymphocytes, measured by flow cytometry. CAF01 also enhanced the protection conferred by the vaccine by reducing the viral load measured in nasal washes by RT-PCR. Finally, CAF01 allowed for dose-reduction and led to higher levels of protection compared to TIV adjuvanted with a squalene emulsion. The data obtained in this human-relevant challenge model supports the potential of CAF01 in future influenza vaccines.",
author = "Martel, {Cyril Jean-Marie} and Agger, {Else Marie} and Poulsen, {Julie Juul} and Jensen, {Trine Hammer} and Lars Andresen and Dennis Christensen and Nielsen, {Lars Peter} and Merete Blixenkrone-M{\o}ller and Peter Andersen and Bent Aasted",
note = "e22891",
year = "2011",
doi = "10.1371/journal.pone.0022891",
language = "English",
volume = "6",
journal = "P L o S One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "8",

}

RIS

TY - JOUR

T1 - CAF01 potentiates immune responses and efficacy of an inactivated influenza vaccine in ferrets

AU - Martel, Cyril Jean-Marie

AU - Agger, Else Marie

AU - Poulsen, Julie Juul

AU - Jensen, Trine Hammer

AU - Andresen, Lars

AU - Christensen, Dennis

AU - Nielsen, Lars Peter

AU - Blixenkrone-Møller, Merete

AU - Andersen, Peter

AU - Aasted, Bent

N1 - e22891

PY - 2011

Y1 - 2011

N2 - Trivalent inactivated vaccines (TIV) against influenza are given to 350 million people every year. Most of these are non-adjuvanted vaccines whose immunogenicity and protective efficacy are considered suboptimal. Commercially available non-adjuvanted TIV are known to elicit mainly a humoral immune response, whereas the induction of cell-mediated immune responses is negligible. Recently, a cationic liposomal adjuvant (dimethyldioctadecylammonium/trehalose 6,6'-dibehenate, CAF01) was developed. CAF01 has proven to enhance both humoral and cell-mediated immune responses to a number of different experimental vaccine candidates. In this study, we compared the immune responses in ferrets to a commercially available TIV with the responses to the same vaccine mixed with the CAF01 adjuvant. Two recently circulating H1N1 viruses were used as challenge to test the vaccine efficacy. CAF01 improved the immunogenicity of the vaccine, with increased influenza-specific IgA and IgG levels. Additionally, CAF01 promoted cellular-mediated immunity as indicated by interferon-gamma expressing lymphocytes, measured by flow cytometry. CAF01 also enhanced the protection conferred by the vaccine by reducing the viral load measured in nasal washes by RT-PCR. Finally, CAF01 allowed for dose-reduction and led to higher levels of protection compared to TIV adjuvanted with a squalene emulsion. The data obtained in this human-relevant challenge model supports the potential of CAF01 in future influenza vaccines.

AB - Trivalent inactivated vaccines (TIV) against influenza are given to 350 million people every year. Most of these are non-adjuvanted vaccines whose immunogenicity and protective efficacy are considered suboptimal. Commercially available non-adjuvanted TIV are known to elicit mainly a humoral immune response, whereas the induction of cell-mediated immune responses is negligible. Recently, a cationic liposomal adjuvant (dimethyldioctadecylammonium/trehalose 6,6'-dibehenate, CAF01) was developed. CAF01 has proven to enhance both humoral and cell-mediated immune responses to a number of different experimental vaccine candidates. In this study, we compared the immune responses in ferrets to a commercially available TIV with the responses to the same vaccine mixed with the CAF01 adjuvant. Two recently circulating H1N1 viruses were used as challenge to test the vaccine efficacy. CAF01 improved the immunogenicity of the vaccine, with increased influenza-specific IgA and IgG levels. Additionally, CAF01 promoted cellular-mediated immunity as indicated by interferon-gamma expressing lymphocytes, measured by flow cytometry. CAF01 also enhanced the protection conferred by the vaccine by reducing the viral load measured in nasal washes by RT-PCR. Finally, CAF01 allowed for dose-reduction and led to higher levels of protection compared to TIV adjuvanted with a squalene emulsion. The data obtained in this human-relevant challenge model supports the potential of CAF01 in future influenza vaccines.

U2 - 10.1371/journal.pone.0022891

DO - 10.1371/journal.pone.0022891

M3 - Journal article

C2 - 21850242

VL - 6

JO - P L o S One

JF - P L o S One

SN - 1932-6203

IS - 8

ER -

ID: 35922775